KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Receivables (2020 - 2022)

Historic Receivables for Recursion Pharmaceuticals (RXRX) over the last 3 years, with Q4 2022 value amounting to $2.8 million.

  • Recursion Pharmaceuticals' Receivables fell 6971.4% to $2.8 million in Q4 2022 from the same period last year, while for Dec 2022 it was $2.8 million, marking a year-over-year decrease of 6971.4%. This contributed to the annual value of $2.8 million for FY2022, which is 6971.4% down from last year.
  • According to the latest figures from Q4 2022, Recursion Pharmaceuticals' Receivables is $2.8 million, which was down 6971.4% from $11.6 million recorded in Q3 2022.
  • Recursion Pharmaceuticals' 5-year Receivables high stood at $11.7 million for Q2 2022, and its period low was $49000.0 during Q2 2021.
  • For the 3-year period, Recursion Pharmaceuticals' Receivables averaged around $5.5 million, with its median value being $2.8 million (2022).
  • Data for Recursion Pharmaceuticals' Receivables shows a peak YoY increase of 2373673.47% (in 2022) and a maximum YoY decrease of 6971.4% (in 2022) over the last 5 years.
  • Recursion Pharmaceuticals' Receivables (Quarter) stood at $156000.0 in 2020, then skyrocketed by 5726.92% to $9.1 million in 2021, then plummeted by 69.71% to $2.8 million in 2022.
  • Its last three reported values are $2.8 million in Q4 2022, $11.6 million for Q3 2022, and $11.7 million during Q2 2022.